Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate symptomatic HIV+, AIDS-related complex (ARC) patients.
Condition or disease
Drug: Interferon alfa-n3
The study has been extended to offer 52 weeks of maintenance therapy after the 10 weeks of the placebo controlled period are concluded successfully.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
Diagnosis of AIDS related complex (ARC).
Given written informed consent.
Been receiving a dose of = or < 600 mg/day of zidovudine (AZT) at least 90 days prior to study entry IF they are currently taking AZT.
Zidovudine (AZT) at a dose = or < 600 mg/day at least 90 days prior to study entry.
Patients with the following conditions or symptoms are excluded:
History of AIDS-defining condition or evidence of AIDS dementia.
Evidence of chronic hepatitis with severe liver dysfunction, or other active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular or psychiatric disorder that would limit the subject's ability to complete the 12 weeks of the study period.
Trimethoprim / sulfamethoxazole (TMP/SMX).
Patients with the following are excluded:
Absolute CD4 count of < 100 or > 350 cells/mm3.
Any disease or disorder listed in Patient Exclusion Co-existing Conditions.
Unlikely or unable to comply with the requirements of the protocol.
Unwilling or unable to give informed consent.
Development of antibodies to interferon during prior interferon therapy that occurred > 3 months prior to study entry.